Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ono, Admid Partner on Novel Antibody Drugs in Oncology | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ono, Admid Partner on Novel Antibody Drugs in Oncology

Ono will evaluate and develop antibody product candidates at the preclinical and clinical stages.

By: Anthony Vecchione

Ono Pharmaceutical Co., Ltd., entered into a drug discovery collaboration agreement with Adimab, LLC, a company involved in the discovery and optimization of fully human monoclonal and bispecific antibodies, to discover and develop innovative antibody drugs in the oncology field.

Under the terms of the agreement, Adimab will discover novel therapeutic antibodies against multiple targets selected by Ono and generate bispecific antibody product candidates. Ono will evaluate and develop such candidates at the preclinical and clinical stages.

Ono will have an option to obtain exclusive rights to globally develop, manufacture, and commercialize the candidates to be generated through this collaboration. Ono will pay to Adimab an upfront payment, R&D funding, success-based research, clinical development, and regulatory milestones, as well as royalties on sales.

“We are actively working to create biologics like antibodies in order to address unmet medical needs for a wide range of diseases including cancers, said Toichi Takino, senior executive officer/executive director, discovery, and research of Ono. “We are very pleased to collaborate with Adimab this time in the oncology area and expect that their multi-specific antibody engineering technologies will create potential novel bispecific antibody candidates. We believe that this collaboration will enhance the creation of our targeted antibody products and bring them for patients with cancers as soon as possible.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics